Active ingredient
- ranibizumab
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD). An audio version is available on eMC.
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV)secondary to pathological myopia. An audio version is available on eMC.
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO). An audio version is available on eMC.
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to retinal vein occlusion (RVO). An audio version is available on eMC.
If you would like to make a comment or send us feedback on this material, click here.
2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ
+44 (0)1276 692 255
+44 (0)1276 698 370
+44 (0)845 741 9442